Get the Stockscreener App
49.23
1.95%
0.94
Akero Therapeutics Inc stock is traded at $49.23, with a volume of 802.55K.
It is up +1.95% in the last 24 hours and down -5.11% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$48.29
Open:
$48.75
24h Volume:
802.55K
Relative Volume:
0.54
Market Cap:
$3.94B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-13.13
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
-0.30%
1M Performance:
-5.11%
6M Performance:
-5.03%
1Y Performance:
+88.55%
1-Day Range:
$47.94
$49.48
1-Week Range:
$47.13
$49.58
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
49.23 | 3.89B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Deutsche Bank AG Has $9.48 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
E Fund Management Co. Ltd. Invests $280,000 in Akero Therapeutics, Inc. $AKRO - MarketBeat
527,004 Shares in Akero Therapeutics, Inc. $AKRO Bought by Lord Abbett & CO. LLC - MarketBeat
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - MSN
Akero Therapeutics (NASDAQ:AKRO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Fox Run Management L.L.C. Makes New $642,000 Investment in Akero Therapeutics, Inc. $AKRO - MarketBeat
Published on: 2025-08-19 16:09:07 - beatles.ru
Andrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Lifesci Capital Has Positive Estimate for AKRO Q3 Earnings - MarketBeat
Jonathan Young Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Investor Suit Over Liver Drug Trials Permanently Tossed - Law360
Latham Wins Dismissal With Prejudice for Pioneering Liver-Disease Drug Company Akero Therapeutics - Latham & Watkins LLP
Akero Defeats Investor Lawsuit Over Liver Drug Trial’s Design - Bloomberg Law News
Analysts Divided on Akero Therapeutics and Kodiak Sciences: AKRO and KOD Ratings Revealed - AInvest
Informed Momentum Co LLC Acquires New Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
20,253 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Aigen Investment Management LP - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.8%Here's Why - MarketBeat
Akero Therapeutics Inc. Shows Risk Reward Favoring Upside2025 Volume Leaders & AI Enhanced Trading Alerts - kangso.co.kr
Akero Therapeutics shares fall 3.81% after-hours following publication of Phase 2b HARMONY trial results in The Lancet. - AInvest
Reversal Confirmed Akero Therapeutics Inc. Stock Rallies Above MAJuly 2025 Institutional & High Conviction Buy Zone Alerts - sundaytimes.kr
Akero Therapeutics shares fall 2.85% intraday as investors take profits and insiders sell stock. - AInvest
Published on: 2025-08-15 12:12:33 - metal.it
Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial - TipRanks
EFX's 96-Week HARMONY Trial: A Paradigm Shift in MASH Treatment and a High-Conviction Buy Case for AKRO - AInvest
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH - GlobeNewswire
Nearly Half of Patients See Liver Fibrosis Improvement: Akero's EFX Drug Shows Promise in 96-Week MASH Study - Stock Titan
Akero Therapeutics: Contrarian Opportunity Amid FDA Approval and Insider Selling - AInvest
Reversing Akero Therapeutics Contrarian Buy Rating to Contrarian Sell Rating - AInvest
Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - Seeking Alpha
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research
Insider Selling and Market Confidence at Akero Therapeutics: A Balancing Act of Strategy and Optimism - AInvest
Akero Therapeutics Insider Sold Shares Worth $1,457,596, According to a Recent SEC Filing - MarketScreener
Akero Therapeutics Insider Sold Shares Worth $597,326, According to a Recent SEC Filing - MarketScreener
Akero Therapeutics COO Young sells $597k in shares By Investing.com - Investing.com Australia
Akero Therapeutics COO Young sells $597k in shares - Investing.com
Akero Therapeutics CEO Cheng sells $1.46 million in stock By Investing.com - Investing.com Canada
Akero Therapeutics CEO Cheng sells $1.46 million in stock - Investing.com India
Akero Therapeutics Executives Sell Shares - TradingView
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Sentiment Turns Positive on Akero Therapeutics Inc. — Reversal AheadTrade Performance Summary & Weekly Momentum Picks - metal.it
Vivo Capital LLC Invests $8.14 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics director Henderson sells $142k in shares By Investing.com - Investing.com Nigeria
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akero Therapeutics Inc Stock (AKRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Young Jonathan | Chief Operating Officer |
Aug 12 '25 |
Option Exercise |
21.10 |
12,500 |
263,750 |
209,984 |
| Young Jonathan | Chief Operating Officer |
Aug 12 '25 |
Sale |
47.79 |
12,500 |
597,326 |
197,484 |
| Cheng Andrew | President and CEO |
Aug 11 '25 |
Sale |
48.59 |
30,000 |
1,457,596 |
490,757 |
| Henderson Jane | Director |
Aug 12 '25 |
Option Exercise |
7.01 |
3,000 |
21,027 |
12,398 |
| Henderson Jane | Director |
Aug 12 '25 |
Sale |
47.46 |
3,000 |
142,371 |
9,398 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):